{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:48:47Z","timestamp":1784872127928,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,13]]},"DOI":"10.7759\/cureus.45195","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T14:17:24Z","timestamp":1694701044000},"source":"Crossref","is-referenced-by-count":1,"title":["Role of Biologic Therapies in the Rheumatic Manifestations of Inflammatory Bowel Disease: A Systematic Analysis"],"prefix":"10.7759","author":[{"given":"Aiswarya","family":"Nag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingle","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakshana","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovish","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binay K","family":"Panjiyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12094","article-title":"The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: a post hoc analysis of the UNITI studies","volume":"9","author":"Narula N","year":"2021","unstructured":"Narula N, Aruljothy A, Wong EC, Homenauth R, Alshahrani AA, Marshall JK, Reinisch W. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: a post hoc analysis of the UNITI studies. United European Gastroenterol J. 2021, 9:581-9. 10.1002\/ueg2.12094","journal-title":"United European Gastroenterol J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.933357","article-title":"The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: a multicenter study","volume":"9","author":"Ferretti F","year":"2022","unstructured":"Ferretti F, Monico MC, Cannatelli R, et al.. The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: a multicenter study. Front Med (Lausanne). 2022, 9:933357. 10.3389\/fmed.2022.933357","journal-title":"Front Med (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2016.1195011","article-title":"Rheumatologic and extraintestinal manifestations of inflammatory bowel diseases","volume":"48","author":"Col\u00eca R","year":"2016","unstructured":"Col\u00eca R, Corrado A, Cantatore FP. Rheumatologic and extraintestinal manifestations of inflammatory bowel diseases. Ann Med. 2016, 48:577-85. 10.1080\/07853890.2016.1195011","journal-title":"Ann Med"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.4078\/jrd.2020.27.3.128","article-title":"Mechanism-based drug therapy of inflammatory bowel disease with special reference to rheumatic disease","volume":"27","author":"Park J","year":"2020","unstructured":"Park J. Mechanism-based drug therapy of inflammatory bowel disease with special reference to rheumatic disease. J Rheum Dis. 2020, 27:128-35.","journal-title":"J Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/387891","article-title":"Management of musculoskeletal manifestations in inflammatory bowel disease","volume":"2015","author":"Sheth T","year":"2015","unstructured":"Sheth T, Pitchumoni CS, Das KM. Management of musculoskeletal manifestations in inflammatory bowel disease. Gastroenterol Res Pract. 2015, 2015:387891. 10.1155\/2015\/387891","journal-title":"Gastroenterol Res Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/2050640620950093","article-title":"Assessment of extraintestinal manifestations in inflammatory bowel diseases: a systematic review and a proposed guide for clinical trials","volume":"8","author":"Guillo L","year":"2020","unstructured":"Guillo L, D'Amico F, Serrero M, et al.. Assessment of extraintestinal manifestations in inflammatory bowel diseases: a systematic review and a proposed guide for clinical trials. United European Gastroenterol J. 2020, 8:1013-30. 10.1177\/2050640620950093","journal-title":"United European Gastroenterol J"},{"key":"ref7","article-title":"Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease","volume":"16","author":"Andrisani G","year":"2012","unstructured":"Andrisani G, Guidi L, Papa A, Armuzzi A. Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. European Review for Medical & Pharmacological Sciences. 2012, 16:","journal-title":"European Review for Medical & Pharmacological Sciences"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211006669","article-title":"Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches","volume":"14","author":"Privitera G","year":"2021","unstructured":"Privitera G, Pugliese D, Lopetuso LR, et al.. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therap Adv Gastroenterol. 2021, 14:17562848211006669. 10.1177\/17562848211006669","journal-title":"Therap Adv Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.5517","article-title":"Rheumatic manifestations of inflammatory bowel disease","volume":"15","author":"Rodr\u00edguez-Reyna TS","year":"2009","unstructured":"Rodr\u00edguez-Reyna TS, Mart\u00ednez-Reyes C, Yamamoto-Furusho JK. Rheumatic manifestations of inflammatory bowel disease. World J Gastroenterol. 2009, 15:5517-24. 10.3748\/wjg.15.5517","journal-title":"World J Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.103564","article-title":"Risks and benefits of biologic therapy for inflammatory bowel diseases","volume":"56","author":"D'Haens G","year":"2007","unstructured":"D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut. 2007, 56:725-32. 10.1136\/gut.2006.103564","journal-title":"Gut"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.2174\/157339707779815731","article-title":"Rheumatic manifestations associated with inflammatory bowel diseases","volume":"3","author":"Podswiadek M","year":"2007","unstructured":"Podswiadek M, Inca RD, Carlo SG, Oliviero F,Punzi L., 2007. Rheumatic manifestations associated with inflammatory bowel diseases. Curr Rheumatol Rev. 2007, 3:47-56.","journal-title":"Curr Rheumatol Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12178-011-9085-8","article-title":"Inflammatory bowel disease associated arthropathy","volume":"4","author":"Arvikar SL","year":"2011","unstructured":"Arvikar SL, Fisher MC. Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskelet Med. 2011, 4:123-31. 10.1007\/s12178-011-9085-8","journal-title":"Curr Rev Musculoskelet Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease","volume":"25","author":"Berg DR","year":"2019","unstructured":"Berg DR, Colombel JF, Ungaro R. The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2019, 25:1896-905. 10.1093\/ibd\/izz059","journal-title":"Inflamm Bowel Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati A","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009, 6:e1000100. 10.1371\/journal.pmed.1000100","journal-title":"PLoS Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5009\/gnl19209","article-title":"Biologics for the management of inflammatory bowel disease:a review in tuberculosis-endemic countries","volume":"14","author":"Banerjee R","year":"2020","unstructured":"Banerjee R, Ali RA, Wei SC, Adsul S. Biologics for the management of inflammatory bowel disease:a review in tuberculosis-endemic countries. Gut Liver. 2020, 14:685-98. 10.5009\/gnl19209","journal-title":"Gut Liver"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-211011","article-title":"Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease","volume":"76","author":"Orlando A","year":"2017","unstructured":"Orlando A, Orlando R, Ciccia F, Renna S, Rizzo A, Cottone M, Macaluso FS. Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. Ann Rheum Dis. 2017, 76:e31. 10.1136\/annrheumdis-2016-211011","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/2050640620958902","article-title":"Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes","volume":"8","author":"Jansen FM","year":"2020","unstructured":"Jansen FM, Vavricka SR, den Broeder AA, de Jong EM, Hoentjen F, van Dop WA. Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes. United European Gastroenterol J. 2020, 8:1031-44. 10.1177\/2050640620958902","journal-title":"United European Gastroenterol J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159\/000502816","article-title":"Therapies in inflammatory bowel disease patients with extraintestinal manifestations","volume":"101 Suppl 1","author":"Juillerat P","year":"2020","unstructured":"Juillerat P, Manz M, Sauter B, Zeitz J, Vavricka SR. Therapies in inflammatory bowel disease patients with extraintestinal manifestations. Digestion. 2020, 101 Suppl 1:83-97. 10.1159\/000502816","journal-title":"Digestion"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx126","article-title":"Ankylosing spondylitis and axial spondyloarthritis in patients with long-term inflammatory bowel disease: results from 20 years of follow-up in the IBSEN study","volume":"12","author":"Ossum AM","year":"2018","unstructured":"Ossum AM, Palm \u00d8, Lunder AK, et al.. Ankylosing spondylitis and axial spondyloarthritis in patients with long-term inflammatory bowel disease: results from 20 years of follow-up in the IBSEN study. J Crohns Colitis. 2018, 12:96-104. 10.1093\/ecco-jcc\/jjx126","journal-title":"J Crohns Colitis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-4971-1","article-title":"Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease","volume":"63","author":"Fleisher M","year":"2018","unstructured":"Fleisher M, Marsal J, Lee SD, Frado LE, Parian A, Korelitz BI, Feagan BG. Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease. Dig Dis Sci. 2018, 63:825-33. 10.1007\/s10620-018-4971-1","journal-title":"Dig Dis Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20196","article-title":"Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease","volume":"13","author":"Barrie A","year":"2007","unstructured":"Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2007, 13:1424-9. 10.1002\/ibd.20196","journal-title":"Inflamm Bowel Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2022.09.009","article-title":"Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study","volume":"55","author":"Livne-Margolin M","year":"2023","unstructured":"Livne-Margolin M, Ling D, Attia-Konyo S, et al.. Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study. Dig Liver Dis. 2023, 55:223-9. 10.1016\/j.dld.2022.09.009","journal-title":"Dig Liver Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2009.238","article-title":"The expanding role of biologic therapy for IBD","volume":"7","author":"Hanauer SB","year":"2010","unstructured":"Hanauer SB. The expanding role of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010, 7:63-4. 10.1038\/nrgastro.2009.238","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-023-03796-2","article-title":"Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports","volume":"17","author":"Momen Majumder MS","year":"2023","unstructured":"Momen Majumder MS, Haq SA, Rasker JJ. Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports. J Med Case Rep. 2023, 17:71. 10.1186\/s13256-023-03796-2","journal-title":"J Med Case Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-016-1283-0","article-title":"Emerging biologics in inflammatory bowel disease","volume":"52","author":"Chan HC","year":"2017","unstructured":"Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017, 52:141-50. 10.1007\/s00535-016-1283-0","journal-title":"J Gastroenterol"},{"key":"ref26","article-title":"Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: a review of the literature","volume":"17","author":"Gold SL","year":"2021","unstructured":"Gold SL, Steinlauf AF. Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: a review of the literature. Gastroenterol Hepatol (N Y). 2021, 17:406-14.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad029","article-title":"Artificial intelligence in inflammatory bowel disease endoscopy: implications for clinical trials","volume":"17","author":"Ahmad HA","year":"2023","unstructured":"Ahmad HA, East JE, Panaccione R, Travis S, Canavan JB, Usiskin K, Byrne MF. Artificial intelligence in inflammatory bowel disease endoscopy: implications for clinical trials. J Crohns Colitis. 2023, 17:1342-53. 10.1093\/ecco-jcc\/jjad029","journal-title":"J Crohns Colitis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/188230-role-of-biologic-therapies-in-the-rheumatic-manifestations-of-inflammatory-bowel-disease-a-systematic-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:52Z","timestamp":1707509092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/188230-role-of-biologic-therapies-in-the-rheumatic-manifestations-of-inflammatory-bowel-disease-a-systematic-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.45195","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,13]]}}}